"We are deeply shocked that a war has broken out in the middle of Europe. This war affects people on both sides of the border, where sons and daughters are committed to a war that only brings suffering and pain. War can never be accepted as a means of resolving conflicts," says Dr. Michael Ramroth, CEO of Biotest AG. "We stand behind the Ukrainian people and condemn the invasion of Russian troops into the country.”
Biotest once again donates blood coagulation drug Haemoctin® to Ukraine
For a year now, the war in Ukraine has dominated the headlines. The suffering of the Ukrainian population continues to affect us all. Biotest has once again decided to help and supply Ukrainian patients free of charge with life-saving medication.
Biotest once again donates blood coagulation drug to Ukraine
PDF, 352 KB
[ Download ]
Biotest donates blood coagulation drug worth 290,000 euros for young Ukrainian refugees
In cooperation with the Deutsche Bluthilfe e.V., Biotest has supplied young haemophilia patients from Ukraine who have fled the war with the blood coagulation drug Haemoctin.
Biotest donates for young Ukrainian refugees
PDF, 331 KB
[ Download ]
500,000 Euros: Biotest makes another donation for blood coagulation drugs Haemoctin® and Haemonine® for young Ukrainian refugees
Biotest has once again donated its Factor VIII and Factor IX preparations to Deutsche Bluthilfe e. V., based in Duisburg, Germany, to ease at least one worry for those affected by congenital blood coagulation disorders and their families.
Patients with hemophilia A ("bleeding disorder") have a congenital deficiency of clotting factor VIII (factor 8) and are constantly at risk of internal bleeding. They therefore need a coagulation factor drug at regular intervals to compensate for the lack of the vital blood protein.
Our product range
Intensive care medicine
Biotest produces several human blood plasma derived concentrates for intensive care medicines. These include Pentaglobin, an IgM enriched immunoglobulin, and other intravenously administered solutions, for the treatment of severe bacterial infections, coagulation disorders, and volume- or protein-substitution.
For the treatment of Haemophilia A and B, Biotest AG manufactures two preparations which derive from human plasma and are designed for intravenous injection.
Biotest produces several antibody concentrates from human blood plasma which are available as ready-to-use solutions. Biotest offers the IVIG preparation Intratect and different hyperimmunoglobulins with increased antibody titers against cytomegaloviruses (CMV), hepatitis B viruses (HBV) or varicella zoster viruses (VZV).
Through its wide range of biological functions, its stability and high solubility, Biotest Human Serum Albumin is suitable for use as a multifunctional excipient for biotechnological, pharmaceutical and diagnostic applications. It is manufactured in a GMP compliant, state-of-the-art facility and complies with the regulatory requirements of multiple health authorities.
28.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
02.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
Announcement according to Article 17 European Market Abuse Regulation (MAR) Peter Janssen appointed new Chairman of the Board of Biotest AG Dreieich, 5 October 2023. In its m ...
[More]
Announcement according to Article 17 European Market Abuse Regulation (MAR) Increase of the EBIT guidance Dreieich, 05 October 2023. Against the background of the agreements ...
[More]
21.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
12.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
07.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
05.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
04.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
10.08.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
27.07.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
01.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
09.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
04.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR) Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised &nbs ...
[More]
25.04.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
20.04.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
30.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
23.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
14.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
Investor Relations
Investor Relations
The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.